Welcome to our dedicated page for Neumora Therapeutics SEC filings (Ticker: NMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pinpointing navacaprant trial costs, cash runway, or when Neumora’s executives sell shares shouldn’t demand hours with dense biotech prose. Yet Neumora Therapeutics’ neuroscience focus means every 8-K safety update, 10-Q R&D footnote, and Form 4 insider trade carries weight for valuation. If you’ve ever typed “Neumora Therapeutics SEC filings explained simply” and still felt lost, this page is built for you.
Stock Titan’s AI breaks down complexity. Our models surface what matters in the exact filing you need: the “Neumora Therapeutics quarterly earnings report 10-Q filing” is summarised into cash burn, trial milestones, and partnership revenue in seconds; “Neumora Therapeutics insider trading Form 4 transactions” trigger real-time alerts, while “Neumora Therapeutics 8-K material events explained” highlights pipeline pauses or fast-track designations. No jargon, just direct answers—perfect for understanding Neumora Therapeutics SEC documents with AI.
Here’s where each form delivers insight:
- 10-K: See risk factors, segment spend, and have the Neumora Therapeutics annual report 10-K simplified for quick reading.
- 10-Q: Track quarter-over-quarter R&D shifts with Neumora Therapeutics earnings report filing analysis.
- Form 4: Follow Neumora Therapeutics executive stock transactions Form 4 and Form 4 insider transactions real-time.
- DEF 14A: Review the Neumora Therapeutics proxy statement executive compensation details without hunting through exhibits.
- 8-K: Immediate context when trials advance or partnerships form.
With comprehensive coverage, AI-powered summaries, and continuous EDGAR feeds, you can finally connect clinical progress to financial impact—faster than scrolling through 300-page PDFs.
Neumora Therapeutics disclosed that K2 HealthVentures Equity Trust LLC and two managing members, Parag Shah and Anup Arora, report beneficial ownership tied to convertible debt that can be converted into Common Stock. Under a loan and security agreement, K2HV Equity has the right to convert up to $10,000,000 of principal into Conversion Shares at the lesser of $0.8774 per share or the lowest effective price in the Issuer's next equity financing; the filers assumed the $0.8774 conversion price.
As a result, the Reporting Persons disclose beneficial ownership of 11,397,310 shares, representing approximately 6.6% of Common Stock on a converted basis. The Schedule shows shared voting and dispositive power over those shares (no sole voting or dispositive power). The reporting address for the filers is provided as 855 Boylston Street, Boston, MA.
FAQ
What is the current stock price of Neumora Therapeutics (NMRA)?
What is the market cap of Neumora Therapeutics (NMRA)?
